'Faslodex' (fulvestrant) is a new type of endocrine treatment for advanced breast cancer, with a distinct and different mode of action. It is an Estrogen Receptor Antagonist with no agonist effects. 'Faslodex' is administered as a once monthly injection.
Did you know?
AstraZeneca has a range of product specific and disease area websites for international healthcare professionals and patients. Links to this information can be found below.
Links to country-specific websites can be found using the AstraZeneca websites list.
If you still have a question regarding our drug portfolio you can Contact us.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD - Stockholm
-
310.10 SEK
At 21-Nov-2009 04:47 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
